Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab in Pediatric Heterozygous Familial Hypercholesterolemia
NCT03510884Phase 3Completed
- Sponsor
- Sanofi
- Start
- May 2018
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies
- Countries
- 24
01
Overview
A Phase 3 trial of alirocumab in heterozygous familial hypercholesterolemia (HeFH), sponsored by Sanofi. Started May 2018; status: completed.
02
Drugs
alirocumab
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT03510884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03510884.